<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="16" ids="53704">APO</z:chebi>-1 is a cell surface molecule that induces <z:mpath ids='MPATH_3'>apoptosis</z:mpath> when ligated with the monoclonal antibody anti-<z:chebi fb="16" ids="53704">APO</z:chebi>-1 </plain></SENT>
<SENT sid="1" pm="."><plain>Expression of <z:chebi fb="16" ids="53704">APO</z:chebi>-1 and response to anti-<z:chebi fb="16" ids="53704">APO</z:chebi>-1 was investigated in a number of Epstein-Barr virus (EBV)-positive and -negative Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cell lines, in EBV-immortalized lymphoblastoid cell lines, and in cells from fresh <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> biopsies </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="16" ids="53704">APO</z:chebi>-1 was not expressed in EBV-negative cell lines and in EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines with a phenotype corresponding to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> biopsy cells (CD10+, CD21-, CD23-, CD30-, CD39-, CDw70-, CD77+) </plain></SENT>
<SENT sid="3" pm="."><plain>Accordingly, fresh <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells obtained from three <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> biopsies were <z:chebi fb="16" ids="53704">APO</z:chebi>-1 negative </plain></SENT>
<SENT sid="4" pm="."><plain>EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines that had acquired a lymphoblastoid phenotype (CD10-, CD21+, CD23+, CD30+, CD39+, CDw70+, CD77-) upon prolonged in vitro cultivation, as well as <z:mpath ids='MPATH_458'>normal</z:mpath> B-lymphoblastoid cell lines, expressed a high density of <z:chebi fb="16" ids="53704">APO</z:chebi>-1 </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="16" ids="53704">APO</z:chebi>-1 may, therefore, be regarded as a B-cell activation marker </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="16" ids="53704">APO</z:chebi>-1 expression is not the only prerequisite for anti-<z:chebi fb="16" ids="53704">APO</z:chebi>-1-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> because 6 of 7 APO-1-expressing EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines were not sensitive to anti-<z:chebi fb="16" ids="53704">APO</z:chebi>-1, whereas <z:hpo ids='HP_0000001'>all</z:hpo> lymphoblastoid cell lines were killed by anti-<z:chebi fb="16" ids="53704">APO</z:chebi>-1 </plain></SENT>
<SENT sid="7" pm="."><plain>The sensitivity of lymphoblastoid cell lines to anti-<z:chebi fb="16" ids="53704">APO</z:chebi>-1-mediated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> may open a new therapeutic approach for the treatment of EBV-induced lymphoproliferative lesions in immunocompromised individuals, because these are composed of cells with a lymphoblastoid phenotype </plain></SENT>
</text></document>